Skip to main content

Advertisement

Table 2 Change in serum sTRAIL levels and association with survival.

From: Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer

Response Status Survival
(month) 		Serum sTRAIL Level (ng/ml)
Alive (n = 7) 20,6 ± 0,5 1,38 ± 0,10
Dead (n = 9) 9,4 ± 0,9 0,92 ± 0,05
Statistical analysis (unpaired
t-test) 		p < 0,05 (p = 0,0001) p < 0,05 (p = 0,0002)
  1. Metastatic colon cancer patients who were treated with bevacizumab, and had increased levels of serum sTRAIL after treatment, had an extended median survival time up to 20.6 months. In contrast, median survival was 9.4 months for patients with decreased or unchanged sTRAIL after the bevacizumab therapy
Back to article page